Preclinical studies revealed an overactive HER pathway characterised as overexpression of HER2 receptor on a breast tumour cell or multiple copies of HER2 gene in the nucleus of the cell being the potential underlying mechanism of HER2+ breast cancer [76]. This evidence concerns the gene ERBB2 and breast neoplasm.